SCHEMBL14320896

SCHEMBL14320896

COc1cccc(Nc2nc(-c3ccccc3)nc3cn[nH]c23)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 16/20 0.68
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
PDE5A O76074 1/20 0.67
ABCB1 P08183 7/20 0.64
ABCC1 P33527 1/20 0.54
PDE4B Q07343 1/20 0.53
KDM4E B2RXH2 1/20 0.52
LMNA P02545 1/20 0.52
TP53 P04637 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
MAPT P10636 1/20 0.52
HPGD P15428 1/20 0.52
MAPK1 P28482 1/20 0.52
CASP1 P29466 1/20 0.52
CYP2C19 P33261 1/20 0.52
CASP7 P55210 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320630 0.87 ABCG2 (0.59) ABCG2MEN1KMT2APDE5AABCB1
SCHEMBL14320756 0.86 ABCG2 (0.67) ABCG2MEN1KMT2APDE5AABCB1
SCHEMBL14320419 0.84 ABCG2 (0.68) ABCG2MEN1KMT2AABCB1ABCC1
SCHEMBL14320390 0.84 ABCG2 (0.53) ABCG2MEN1KMT2APDE5AABCB1
SCHEMBL14320737 0.84 ABCG2 (0.53) ABCG2MEN1KMT2APDE5AABCB1
SCHEMBL14320626 0.83 ABCG2 (0.66) ABCG2MEN1KMT2APDE5AABCB1
SCHEMBL14320666 0.82 KDM1A (0.53) ABCG2MEN1KMT2APDE5AABCB1
SCHEMBL1063481 0.81 ABCG2 (1.00) ABCG2MEN1KMT2APDE5AABCB1
SCHEMBL28086152 0.81 ABCG2 (0.67) ABCG2ABCB1ABCC1TP53MAPT
SCHEMBL13741113 0.79 MEN1 (0.55) ABCG2MEN1KMT2APDE5AABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK ABCG2 3810/4885MEN1 544/4885KMT2A 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.